Senior 60+

Quick Summary

• Protein per-meal threshold rises with age. The "anabolic resistance" of aging muscle means per-meal leucine triggering of MPS requires closer to 35–40 g protein per meal in older adults vs ~20 g in younger adults (Macnaughton 2016 PMID 27511985 supports the 40 g whole-body context). The Morton 2018 (PMID 28698222) 1.6 g/kg/day threshold remains the daily anchor. The PROVIDE trial (Bauer 2015 PMID 26170041) demonstrated functional gain in sarcopenic adults aged 65+ at 20 g whey + 3 g leucine + 800 IU vitamin D3 daily for 13 weeks, WITHOUT an exercise requirement.
• Vitamin D3 benefit depends on baseline status. Bone mineral density benefit is established in deficient populations (Kazemian 2023 meta PMID 36308775); fracture reduction is most reproducibly observed in deficient populations with concurrent calcium (Kong 2022 PMID 35504603). The LeBoff 2022 VITAL fracture sub-study (PMID 35939577 · n=25,871 generally healthy adults · 2000 IU/day for 5.3 years) reported NO significant reduction in total, non-vertebral, or hip fracture in already-replete adults. The honest read: D3 is for the deficient, not a uniform geriatric supplement.
• Omega-3 memory benefit is real in the mild-complaint cohort. Yurko-Mauro 2015 meta-analysis (PMID 25786262) supports DHA-containing supplementation in older adults with mild memory complaints. Established Alzheimer's disease evidence is null (PMID 38924283).
• B12 absorption declines with age. Atrophic gastritis, chronic PPI / H2 blocker use, and metformin therapy all reduce B12 absorption efficiency in older adults. Supplementation is most defensible in documented deficiency or a known absorption-impairing context.
• Astaxanthin has healthy-aging cross-system signals. Skin moisture and elasticity (Zhou 2021 PMID 34578794), fatigue and motor function (Liu 2024 PMID 38243785). Cognition in healthy adults is unsettled.
• Sarcopenia is a defined muscle disease with EWGSOP2 criteria. The Cruz-Jentoft 2019 Age Ageing consensus (PMID 30312372) updated the European definition: sarcopenia is "muscle failure rooted in adverse muscle changes that accrue across a lifetime," with low muscle strength as the primary diagnostic feature (grip strength <27 kg in men and <16 kg in women), confirmed by low muscle quantity / quality. This is a definition + diagnosis reference, not a treatment claim.
• Exercise is the dominant lever; nutrition is the adjunct. The Beaudart 2017 systematic review (PMID 28251287 · Osteoporos Int · 37 RCTs) reported that physical exercise alone substantially improved muscle mass in ~79% and strength in ~83% of studies, while combined nutrition adjuncts provided additional benefit in only ~23.5% / 22.8%. Resistance training is the structural lever; protein + D3 supplementation is the marginal adjunct that helps when dietary adequacy is also met.
• This is not medical advice. Senior supplementation decisions belong with your physician and care team. The framework below is mechanism and evidence mapping, reproduced for educational reference — not for self-administration.

Identified Nutrition Gaps — Senior Life-Stage

The four gaps below are the most common nutrition-adequacy concerns in the senior 60+ cohort across community-dwelling adults. Each gap maps to one of the related ingredients in the Evidence Stack.

• Protein adequacy (per-meal threshold and total daily intake during reduced appetite and reduced anabolic sensitivity)
• Vitamin D3 baseline planning (replete vs deficient status determines benefit; fracture reduction is NOT uniform in already-replete adults)
• Omega-3 source selection (DHA for memory in mild-complaint cohort; EPA-predominant for mood; cardiovascular outcomes conditional)
• B12 review (absorption efficiency declines with age and chronic acid-suppression medication use)

The Evidence Stack

The "evidence" column below describes the strength and direction of the senior-context outcome evidence in qualitative terms — well-established, robust, moderate–mixed, preliminary–emerging, or null–negative. The S/A/B/C tier that grades how extensively an ingredient is studied (its evidence volume) lives on each linked ingredient page, not here.

How It Works

Aging changes the nutrition math by a different route for each nutrient — protein through the rising per-meal anabolic-resistance threshold, vitamin D3 through declining cutaneous synthesis and status-dependent benefit, DHA through brain membrane composition in the mild-memory-complaint cohort, B12 through age-related absorption decline, and astaxanthin through multi-system healthy-aging signals — all framed by exercise as the dominant structural lever.

Anabolic resistance — the per-meal protein threshold rises with age. Older skeletal muscle requires a larger per-meal protein bolus (closer to 35 to 40 g) to clear the mTORC1 / leucine threshold and trigger maximal MPS — compared with the ~20 g sufficient for single-muscle-group training in younger adults. The Macnaughton 2016 (PMID 27511985) whole-body data anchor the 40 g target; the Cermak 2012 meta-analysis (PMID 23134885) supports protein supplementation augmenting the response to resistance training in older adults. The PROVIDE trial (Bauer 2015 PMID 26170041) demonstrated daily 20 g whey + 3 g leucine + 800 IU D3 in sarcopenic adults aged 65+ produced functional gain WITHOUT requiring an exercise component.

Vitamin D status declines and benefit depends on it. Cutaneous vitamin D synthesis declines with age (~70% reduction by age 70 vs young adult), and renal 1α-hydroxylation also declines. Where dietary intake and sun exposure are insufficient, baseline 25-OH-vitamin D status frequently drops below the deficient threshold. This is where benefit shows: Kazemian 2023 BMD meta-analysis (PMID 36308775) and Kong 2022 fracture meta-analysis (PMID 35504603 · 800-1000 IU/day daily-dose optimal) both anchor benefit in deficient populations. The LeBoff 2022 VITAL fracture sub-study (PMID 35939577) is the counter-evidence: 25,871 generally healthy adults (mostly already-replete), 5.3 years at 2000 IU/day, NO significant reduction in total, non-vertebral, or hip fracture. D3 is for the deficient.

DHA in brain membrane phospholipids and the mild-memory-complaint cohort. DHA is the dominant fatty acid in brain synaptic membranes; the Yurko-Mauro 2015 meta-analysis (PMID 25786262) supports DHA-containing supplementation benefit in older adults with mild memory complaints. The 2024 dose-response meta (PMID 38468309) extends this signal in healthy adults without dementia. The honest counter-evidence: established Alzheimer's disease trials (PMID 38924283, PMID 28986068) show null — omega-3 is for cognitive maintenance, not Alzheimer's treatment. See the standalone omega-3 single-product page plus the EPA (fish-first) and DHA (algae first-line) monomer pages.

B12 absorption efficiency drops with age. Atrophic gastritis (loss of gastric acid and intrinsic factor), chronic PPI / H2 blocker use, and metformin therapy all impair the gastric and ileal steps of B12 absorption. Plasma B12 deficiency in older adults is frequently iatrogenic-pharmacologic rather than dietary; this is the population where B12 supplementation is most defensible. Routine high-dose B12 in already-replete adults without absorption issues is not evidence-supported as a uniform geriatric supplement.

Astaxanthin healthy-aging signals. Zhou 2021 (PMID 34578794) supports skin moisture and elasticity (older-adult skin aging is the relevant context). Liu 2024 (PMID 38243785) supports fatigue and motor function. Liu 2021 (PMID 34110707) is an elderly aerobic-training trial; Liu 2018 (PMID 30259703) is a sarcopenia-context trial. The cluster supports astaxanthin as a healthy-aging multi-system signal — not as a treatment for any specific aging-related disease.

Sarcopenia as a defined muscle disease — EWGSOP2 framework. The Cruz-Jentoft 2019 EWGSOP2 European consensus paper (PMID 30312372 · Age Ageing) defines sarcopenia as a muscle disease rooted in adverse muscle changes that accrue across a lifetime; the diagnostic flow uses the F-A-C-S (Find-Assess-Confirm-Severity) algorithm, with low muscle strength (grip strength <27 kg in men, <16 kg in women) as the primary criterion, confirmed by low muscle quantity and quality. This is the definition + diagnosis framework that underlies the PROVIDE trial inclusion criteria and the Beaudart 2017 SR cohort. It is referenced here for transparency, not as a treatment claim.

Exercise is the dominant lever; nutrition is the adjunct — Beaudart 2017 SR. The Beaudart 2017 Osteoporos Int systematic review (PMID 28251287 · 37 RCTs) is the honest framing anchor for senior nutrition strategy: physical exercise alone substantially improved muscle mass in approximately 79% of included studies and muscle strength in approximately 83%, while nutritional adjuncts provided additional benefit in only approximately 23.5% and 22.8% respectively. The transparent read: resistance training is the structural lever for senior muscle preservation; protein-adequacy and D3 supplementation are marginal adjuncts that compound when dietary intake is adequate — not standalone replacements for resistance training.

Body systems engaged: Musculoskeletal · Neurological & Cognitive · Cardiovascular · Mitochondrial & Cellular Energy. Mechanism tags: mTOR regulation · Free radical scavenging · Neurotransmitter modulation.

What the Trials Show — Including the Nulls

The VITAL discontinuation follow-up matters. Costenbader 2024 (PMID 38272846) reported that the autoimmune protective effect of vitamin D3 was no longer statistically significant two years after randomized treatment ended. D3 should not be described as conferring "long-lasting" autoimmune protection — continuous supplementation appears necessary in the populations where benefit was observed.

Astaxanthin is not a "youth in a bottle." The Zhou 2021 meta-analysis (PMID 34578794) supports moisture and elasticity but NOT pooled wrinkle-depth reduction. Astaxanthin should not be characterized as anti-aging in the sense of reversing aging or producing visible cosmetic miracles.

B12 supplementation is most defensible in documented deficiency or a known absorption-impairing context. Routine high-dose B12 in already-replete adults is not evidence-supported as a uniform geriatric supplement.

Supplements are the marginal lever; resistance training and dietary protein adequacy are the foundational levers. The Beaudart 2017 SR (PMID 28251287 · 37 RCTs) is the honest counter to "take these supplements and your sarcopenia is solved" framing: exercise alone improved muscle mass in ~79% of trials and strength in ~83%; nutrition adjuncts added benefit in only ~23%. The Cermak 2012 meta (PMID 23134885) shows protein supplementation augments resistance-training response — but the augmentation is conditional on resistance training being present. Protein supplementation without resistance training is a much weaker lever than the marketing of "muscle-preservation drinks" suggests.

Sarcopenia definition is a starting point, not a guarantee of treatment response. The Cruz-Jentoft 2019 EWGSOP2 paper (PMID 30312372) provides the diagnostic framework but is explicit that effective interventions in diagnosed sarcopenia are typically multi-modal (exercise + nutrition + chronic-disease management). A diagnosis confirms the muscle-failure phenotype; it does not confer automatic response to any single supplement.

Practical Notes

Timing, pairing, and realistic timeframes matter more than megadosing — protein needs per-meal distribution and a resistance-training partner, D3 is status-led, and hard endpoints (fracture, cardiovascular events) require multi-year follow-up. Doses below reflect published trial protocols and diagnostic consensus, reproduced for reference only.

Whey + Leucine + Vitamin D3 · the PROVIDE triad. Bauer 2015 (PMID 26170041) — 20 g whey + 3 g leucine + 800 IU D3 daily for 13 weeks produced functional gain (grip strength, chair-rise) in sarcopenic adults aged 65+ without exercise. This is the single most evidence-supported senior-context combination in the literature, and it sits on top of dietary protein intake, not in place of it.

Protein + Resistance Training · the structural pair. Cermak 2012 (PMID 23134885) — protein supplementation augments the adaptive response to resistance training in older adults. Pairing adequate per-meal protein (~35–40 g) with structured resistance training is the structural answer to sarcopenia; Beaudart 2017 (PMID 28251287) reframes the hierarchy with exercise as the dominant lever and nutrition compounding in roughly 23% of contexts, typically where protein adequacy is the gating factor. Prioritize a structured progressive resistance-training routine 2 to 3 times per week plus per-meal protein adequacy; layer PROVIDE-style supplemental adjuncts when dietary intake falls short.

Vitamin D3 + Calcium · the bone pair (status-dependent). Kong 2022 (PMID 35504603) — the fracture-reduction signal is most robustly observed in deficient populations with concurrent calcium intake. In already-replete adults, the pair does not produce uniform fracture reduction (LeBoff 2022 PMID 35939577). Discuss 25-OH-vitamin D testing with your physician before assuming D3 supplementation is appropriate.

DHA + cognitive engagement · the mild-memory-complaint pair (mechanism). DHA membrane composition plus cognitive engagement (reading, learning, social) is the conventional framing in the healthy-aging cognition literature. No direct clinical synergy trial in this specific combination, but it is the implicit framework in the Yurko-Mauro 2015 cohort. On the omega-3 safety ceiling, FDA guidance is ≤2 g/day EPA+DHA from supplements, with total intake up to 3 g/day considered GRAS.

Realistic timeframes. 13 weeks for functional gain on the PROVIDE protocol (Bauer 2015 PMID 26170041); 12 to 24 weeks for memory benefit in the mild-complaint cohort (Yurko-Mauro 2015 PMID 25786262); roughly 8 to 12 weeks for skin moisture and elasticity with astaxanthin (Zhou 2021 PMID 34578794); and 5+ years for cardiovascular and bone hard endpoints (LeBoff 2022 VITAL PMID 35939577 followed adults 5.3 years).

Lifetime substrate · dietary adequacy. Senior nutrition adequacy is downstream of long-term dietary and lifestyle adequacy and of resistance training. Supplementation is layered on top of a robust dietary and activity foundation, not a replacement for it.

Related Goals & Ingredients

• longevity-stack
• joint-bone
• heart-health
• Cognitive Support — DHA memory benefit and the established-Alzheimer's-null finding are the shared anchors.
• Athletic Performance — the per-meal MPS and 1.6 g/kg/day Morton 2018 (PMID 28698222) framework translates to the senior context with the anabolic-resistance per-meal upward adjustment.
• GLP-1 Companion — overlap when senior adults are also on GLP-1 medication; lean-mass preservation priority is compounded.
• Pregnancy — different life-stage where DHA + omega-3 cross-references reappear.
• Linked ingredients: Protein · Vitamin D3 · Omega-3 (with EPA · DHA · Algae Oil) · Vitamin B12 · Astaxanthin.

Frequently Asked Questions

References

All PMIDs verified against PubMed. Effect sizes are reported as published.

Citation corrections. A proposed Daly 2014 bone-density anchor (PMID 24787496) was not used — that PMID indexes Bhupathiraju 2014 on glycemic index and type-2 diabetes risk; only verified anchors are cited.

1. PMID 26170041 · Bauer et al. (2015) · PROVIDE trial · J Am Med Dir Assoc · 20 g whey + 3 g leucine + 800 IU D3 daily for 13 wk in sarcopenic adults 65+ · functional gain without exercise requirement
2. PMID 28698222 · Morton et al. (2018) · protein supplementation / resistance training meta-analysis · ~1.6 g/kg/day daily threshold anchor
3. PMID 27511985 · Macnaughton et al. (2016) · whole-body MPS · 40 g protein bolus context
4. PMID 23134885 · Cermak et al. (2012) · protein supplementation augments resistance-training response in older adults (meta-analysis)
5. PMID 18175749 · Houston et al. (2008) · Health ABC cohort · dietary protein and lean-mass change quintiles
6. PMID 28251287 · Beaudart et al. (2017) · Osteoporos Int · 37-RCT SR on nutrition + physical activity in sarcopenia · exercise dominant lever ~79% muscle mass / ~83% strength · nutrition marginal adjunct ~23%
7. PMID 30312372 · Cruz-Jentoft et al. (2019) · EWGSOP2 · Age Ageing · sarcopenia definition + diagnostic criteria · grip strength <27 kg M / <16 kg F · F-A-C-S algorithm
8. PMID 36308775 · Kazemian et al. (2023) · vitamin D and bone mineral density meta-analysis
9. PMID 35504603 · Kong et al. (2022) · vitamin D and fracture daily-dose meta-analysis · 800-1000 IU/day daily-dose optimal in deficient populations with calcium
10. PMID 35939577 · LeBoff et al. (2022) · VITAL fracture sub-study · n=25,871 generally healthy adults · 2000 IU/day for 5.3 years · NO significant reduction in total, non-vertebral, or hip fracture in already-replete adults
11. PMID 28202713 · Martineau et al. (2017) · vitamin D respiratory-infection IPD meta-analysis · deficient subgroup OR 0.58
12. PMID 38272846 · Costenbader et al. (2024) · VITAL discontinuation follow-up · autoimmune protective effect no longer significant two years after treatment ended
13. PMID 25786262 · Yurko-Mauro et al. (2015) · DHA and memory meta-analysis · benefit in older adults with mild memory complaints
14. PMID 38468309 · 2024 omega-3 dose-response meta-analysis · cognition in healthy adults without dementia
15. PMID 38924283 · established Alzheimer's disease omega-3 trial · null
16. PMID 28986068 · established Alzheimer's disease omega-3 trial · null
17. PMID 37264945 · omega-3 EPA+DHA triglyceride-lowering dose-response meta-analysis
18. PMID 34578794 · Zhou et al. (2021) · astaxanthin skin moisture and elasticity meta-analysis · wrinkle-depth not pooled-significant
19. PMID 38243785 · Liu et al. (2024) · astaxanthin fatigue and motor function meta-analysis
20. PMID 32755613 · Xia et al. (2020) · astaxanthin cardiovascular meta-analysis · HDL-C significant · BMI null
21. PMID 34110707 · Liu et al. (2021) · astaxanthin elderly aerobic-training trial
22. PMID 30259703 · Liu et al. (2018) · astaxanthin sarcopenia-context trial
23. PMID 35927255 · Igarashi et al. (2022) · NMN 250 mg/day 12 wk in healthy older Japanese men · walking speed and grip strength
24. PMID 35215405 · Kim et al. (2022) · NMN afternoon-dosing chronobiology · five-times sit-to-stand, sleep, fatigue

Coverage Notes

Ingredient-correction notes. Omega-3 links resolve to the omega-3 single-product page plus the standalone EPA (fish-first) and DHA (algae first-line) monomer pages; any "omega-3/algae" related ingredient resolves to Algae Oil. FDA omega-3 guidance is ≤2 g/day EPA+DHA from supplements, with total intake up to 3 g/day considered GRAS. The Yurko-Mauro 2015 memory signal is in the mild-memory-complaint cohort and is presented distinctly from the null established-Alzheimer's evidence — the two are not blurred into a single cognitive-enhancement claim.

Regulatory boundary and educational reaffirmation. This is a non-commercial educational evidence-framework page, not a prescriptive supplementation plan. It makes no claims to diagnose, treat, cure, or prevent sarcopenia, Alzheimer's disease, osteoporosis, or any other medical condition. All senior supplementation decisions belong with a qualified physician and care team. Diagnostic consensus documents (e.g. EWGSOP2 sarcopenia criteria) are cited as reference only; this page targets international markets and does not address China NMPA positioning.